Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL670770 | 0.79 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2PKMGAAMAPT | |
| SCHEMBL13979120 | 0.78 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2PKMGAAPOLB | |
| SCHEMBL671879 | 0.77 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2PKMGAAMAPT | |
| SCHEMBL673608 | 0.76 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2PKMGAAPOLB | |
| SCHEMBL17369604 | 0.76 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2PKMGAAPOLB | |
| SCHEMBL20252796 | 0.76 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2PKMGAAPOLB | |
| SCHEMBL4813897 | 0.74 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2PKMGAAPOLB | |
| SCHEMBL17369605 | 0.73 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2PKMGAAPOLB | |
| SCHEMBL5197559 | 0.73 | OPRM1 (0.46) | MEN1TP53KMT2AATM | |
| SCHEMBL27715704 | 0.70 | TAAR1 (0.47) | ALDH1A1SMN1; SMN2PKMMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319213-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX ADVANCED BIOCHEMICAL COMPOUNDS – BIOMEDIZINISCHE FORSCHUNGSREAGENZIEN GMBH (DE) | 2025-10-16 | — | — | US | disclosed |
| EP-4529473-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH (DE) | 2025-04-02 | — | — | EP | disclosed |
| WO-2023227535-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (DE) | 2023-11-30 | — | — | WO | disclosed |
| EP-4282438-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX Advanced Biochemical Compounds GmbH (DE) | 2023-11-29 | — | — | EP | disclosed |
| EP-2605801-A1 | IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS | GE Healthcare UK Limited (GB) | 2013-06-26 | — | — | EP | disclosed |
| US-20130149249-A1 | IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS | GE HEALTHCARE LIMITED (GB) | 2013-06-13 | — | — | US | disclosed |
| US-20130149249-A1 | IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS | GE HEALTHCARE LIMITED (GB) | 2013-06-13 | — | — | US | disclosed |
| US-20130149249-A1 | IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS | GE HEALTHCARE LIMITED (GB) | 2013-06-13 | — | — | US | disclosed |
| WO-2012022812-A1 | IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS | GE HEALTHCARE LIMITED (GB) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012022812-A1 | IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS | GE HEALTHCARE LIMITED (GB) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130149249-A1 | IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS | CTPS1, CTPS2, MPI | ALDH1A1 1652/4885SMN1; SMN2 4820/4885PKM 1093/4885 |
| US-20250319213-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | MARS1, MARS2, BCAT1 | ALDH1A1 3187/4885SMN1; SMN2 3434/4885PKM 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.